Analyzing InMed Pharmaceuticals (INM) and Its Rivals

InMed Pharmaceuticals (NASDAQ:INM) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it contrast to its peers? We will compare InMed Pharmaceuticals to related companies based on the strength of its analyst recommendations, profitability, earnings, dividends, institutional ownership, valuation and risk.

Profitability

This table compares InMed Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
InMed Pharmaceuticals	N/A	-156.08%	-123.90%
InMed Pharmaceuticals Competitors	-2,372.59%	-220.83%	-15.99%

Valuation & Earnings

This table compares InMed Pharmaceuticals and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
InMed Pharmaceuticals	$4.94 million	-$12.56 million	-1.02
InMed Pharmaceuticals Competitors	$3.55 billion	$3.17 billion	547.98

InMed Pharmaceuticals’ peers have higher revenue and earnings than InMed Pharmaceuticals. InMed Pharmaceuticals is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Institutional and Insider Ownership

20.1% of InMed Pharmaceuticals shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 0.9% of InMed Pharmaceuticals shares are held by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

InMed Pharmaceuticals has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals’ peers have a beta of -3.79, indicating that their average share price is 479% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and target prices for InMed Pharmaceuticals and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InMed Pharmaceuticals	1	0	0	0	1.00
InMed Pharmaceuticals Competitors	7769	13855	25724	1032	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.46%. Given InMed Pharmaceuticals’ peers stronger consensus rating and higher probable upside, analysts clearly believe InMed Pharmaceuticals has less favorable growth aspects than its peers.

Summary

InMed Pharmaceuticals peers beat InMed Pharmaceuticals on 10 of the 13 factors compared.

About InMed Pharmaceuticals

InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products. The company operates through two segments, the InMed and the BayMedica. The InMed segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with high unmet medical needs. The company’s lead product is INM-755, a cannabinol topical skin cream, completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-900 for neurodegenerative diseases. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach, for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.